P414 Obesity is associated with a higher risk of immunogenicity to adalimumab, but not to infliximab in patients with Inflammatory Bowel DiseaseRemi Mahmoud, Bas Oldenburg, P van Boeckel et al.|Journal of Crohn s and Colitis|2021Cited by 3
DOP75 Loss-of-response and immunogenicity following immunomodulator withdrawal from anti-tumour necrosis factor alpha combination therapy: Results from a large retrospective cohort studyRemi Mahmoud, Bas Oldenburg, J Schultheiss et al.|Journal of Crohn s and Colitis|2021Cited by 0
P299 Loss-of-response to anti-tumour necrosis factor-α critically depends on treatment duration in patients with Inflammatory Bowel DiseaseJ Schultheiss, Bas Oldenburg, Herma H. Fidder et al.|Journal of Crohn s and Colitis|2021Cited by 0